WallStSmart

Insmed Inc (INSM)vsKalvista Pharmaceuticals Inc (KALV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 42426% more annual revenue ($606.42M vs $1.43M). KALV leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

KALV

Avoid

30

out of 100

Grade: F

Growth: 6.3Profit: 2.5Value: 5.0Quality: 4.0
Piotroski: 1/9Altman Z: -4.63

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

KALV1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
30.7%10/10

Revenue surging 30.7% year-over-year

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

KALV4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$859.29M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : KALV

The strongest argument for KALV centers on Revenue Growth. Revenue growth of 30.7% demonstrates continued momentum.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : KALV

The primary concerns for KALV are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 8.80 is elevated, increasing financial risk.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while KALV is a hypergrowth play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

KALV is growing revenue faster at 30.7% — sustainability is the question.

KALV generates stronger free cash flow (-33M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Kalvista Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops, and markets small-molecule protease inhibitors for illnesses with unmet needs. The company is headquartered in Cambridge, Massachusetts.

Visit Website →

Want to dig deeper into these stocks?